Alcon AG

Alcon AG(ALC)股票分析

$72.240

+0.491 (+0.68%)收盘时

Loading chart…
High
73.520
Open
71.720
VWAP
72.49
Vol
1.33M
Mkt Cap
44.25B
Low
71.720
Amount
96.28M
EV/EBITDA, TTM
13.75

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.

www.alcon.ch

AI analysis of Alcon AG (ALC)

hold

Alcon AG (ALC) is currently priced at $72.01, which is below the average analyst price target of $79 to $85. However, the stock has a low RSI of 37.964, indicating it may be oversold, but the recent earnings report showed a significant drop in net income to $0.00 in Q2 2026, which raises concerns. The main risk is the downgrade from BNP Paribas, which reflects a challenging outlook for the company in the near future.

估值指标

The current forward P/E ratio for Alcon AG (ALC) is 20.70, compared to its 5-year average forward P/E of 27.52.

Forward P/E

Undervalued
5Y Average P/E
27.52
Current P/E
20.70
高估
31.90
低估
23.14

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
17.55
Current EV/EBITDA
13.75
高估
20.06
低估
15.03

Forward P/S

Undervalued
5Y Average P/S
3.92
Current P/S
2.95
高估
4.44
低估
3.40

Alphio AI Price Scenarios for ALC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ALC

$97.66

情景价格

B

Base

Base · 50%ALC

$95.34

情景价格

B

Bear

Bear · 25%ALC

$83.95

情景价格

Whales holding ALC

S

Sofinnova Investments, Inc.

+ HoldingALC

+25.58%

3M Return

V

Vestal Point Capital, LP

+ HoldingALC

+18.59%

3M Return

B

Bellevue Asset Management AG

+ HoldingALC

+11.71%

3M Return

C

Carmignac Gestion SA

+ HoldingALC

+8.68%

3M Return

M

Mercer Investments LLC

+ HoldingALC

+8.06%

3M Return

B

Beck, Mack & Oliver LLC

+ HoldingALC

+7.90%

3M Return

事件时间线

2026-09-03 (ET)

09:30:00

Alcon Launches UNITY M Surgical Microscope

2026-08-24 (ET)

09:00:00

Gorilla Technology Borrow Rate Increases to 26.85%

2026-08-11 (ET)

09:00:00

Stock Futures Modestly Higher as Investors Await CPI Report

2026-08-10 (ET)

19:30:00

Babcock & Wilcox Enterprises Shares Up 39.5%

资讯

ALC FAQ — answered by Alphio AI

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries. It operates in the Healthcare sector.

Alcon AG (ALC) is currently priced at $72.01, which is below the average analyst price target of $79 to $85. However, the stock has a low RSI of 37.964, indicating it may be oversold, but the recent earnings report showed a significant drop in net income to $0.00 in Q2 2026, which raises concerns. The main risk is the downgrade from BNP Paribas, which reflects a challenging outlook for the company in the near future.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始